Evidence map›Paper›PMID 37251069›Full record

ArticleFrontiers in psychology2023

ARC: a framework for access, reciprocity and conduct in psychedelic therapies.

Meg J Spriggs, Ashleigh Murphy-Beiner, Roberta Murphy, Julia Bornemann, Hannah Thurgur, Anne K Schlag

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026
    Review
  3. Article
  4. Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.Current topics in behavioral neurosciences · 2026
    Review
  5. Review
  6. Article
  7. Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Meg J SpriggsDivision of Psychiatry, Department of Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, United Kingdom.
Ashleigh Murphy-BeinerDivision of Psychiatry, Department of Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, United Kingdom.
Roberta MurphyDivision of Psychiatry, Department of Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, United Kingdom.
Julia BornemannDivision of Psychiatry, Department of Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, United Kingdom.
Hannah ThurgurDrug Science, London, United Kingdom.
Anne K SchlagDivision of Psychiatry, Department of Brain Sciences, Centre for Psychedelic Research, Imperial College London, London, United Kingdom.
Imperial College London · GBRoyal Holloway University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of psychedelic assisted therapy (PAT) is growing at an unprecedented pace. The immense pressures this places on those working in this burgeoning field have already begun to raise important questions about risk and responsibility. It is imperative that the development of an ethical and equitable infrastructure for psychedelic care is prioritized to support this rapid expansion of PAT in research and clinical settings. Here we present Access, Reciprocity and Conduct (ARC); a framework for a culturally informed ethical infrastructure for ARC in psychedelic therapies. These three parallel yet interdependent pillars of ARC provide the bedrock for a sustainable psychedelic infrastructure which prioritized equal access to PAT for those in need of mental health treatment (Access), promotes the safety of those delivering and receiving PAT in clinical contexts (Conduct), and respects the traditional and spiritual uses of psychedelic medicines which often precede their clinical use (Reciprocity). In the development of ARC, we are taking a novel dual-phase co-design approach. The first phase involves co-development of an ethics statement for each arm with stakeholders from research, industry, therapy, community, and indigenous settings. A second phase will further disseminate the statements for collaborative review to a wider audience from these different stakeholder communities within the psychedelic therapy field to invite feedback and further refinement. By presenting ARC at this early stage, we hope to draw upon the collective wisdom of the wider psychedelic community and inspire the open dialogue and collaboration upon which the process of co-design depends. We aim to offer a framework through which psychedelic researchers, therapists and other stakeholders, may begin tackling the complex ethical questions arising within their own organizations and individual practice of PAT.

Indexed as

co-designequityethicspsychedelic assisted therapy (PAT)psychotherapy

Identifiers

PMID37251069
PMCPMC10211333
OpenAlexW4378745947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.